George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 49.75
Bid: 49.50
Ask: 50.00
Change: 0.75 (1.53%)
Spread: 0.50 (1.01%)
Open: 48.75
High: 49.75
Low: 49.00
Prev. Close: 49.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down

Wed, 14th Jul 2021 11:30

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Symphony Environmental Technologies, up 11% at 21.17 pence, 12-month range 10.65p-47.0p. The anti-microbial plastic technologies firm receives approval from the US Food & Drug Administration for its d2p antimicrobial food contact technology.

----------

88 Energy, up 7.9% at 1.89p, 12-month range 0.24p-4.70p. The Alaska-focused oil exploration and appraisal company says additional phase one geochemical analysis of fluid extracts from Merlin-1 well core samples again demonstrates the presence of hydrocarbons. Results from phase two of side-wall core trim analysis are expected in the next few weeks. Phase two is designed to confirm not only the presence of oil but also the nature of the source rock, to help understand the likely quality of the oil as well as migration pathways.

----------

Alpha FX Group, up 6.7% at 1,665.00p, 12-month range 677p-1,720p. The foreign exchange risk management and international payments firm says trading in the first half ended June 30 has been "strong" across its business, with revenue up 89% year on year at GBP34 million. Adds 84 new clients and notes average revenue per client continued to increase. The company expects to exceed current internal expectations for 2021, on the back of continued strong trading. In 2020, saw revenue of GBP46.2 million with pretax profit of GBP17.1 million.

----------

Avacta, up 5.9% at 143.56p, 12-month range 88.66p-291.80p. The developer of diagnostics and cancer therapies says Life Sciences unit gets ISO 13485 certification for the quality management system for the manufacture and distribution of Affimer reagents for use in lateral flow, ELISA and immunodiagnostic in-vitro diagnostic devices.

----------

Fulcrum Utility Services, up 5.6% at 32.74p, 12-month range 28.25p-43.60p. The energy and multi-utility services provider wins new GBP4.9 million multi-utility infrastructure contract from unnamed "large investor developer", for a "major" new employment park in the West Midlands. As part of the contract, the company will design and install a high voltage primary substation and the electricity, water, and gas infrastructure to "energise and power" the new development.

----------

AIM - LOSERS

----------

Tern, down 13% at 19.40p, 12-month range 5.50p-31.67p. The investment firm completes fundraise at the issue price of 18.8p per share. The retail offer and subscription were both oversubscribed and the company said it raised GBP2 million and GBP4 million, respectively. "We intend to utilise the proceeds to maximise the value to our shareholders of our portfolio, and I look forward to providing further updates in due course," says Chief Executive Al Sisto.

----------

Kromek Group, down 7.0% at 15.00p, 12-month range 7.66p-25.20p. The detection technology firm says revenue totalled GBP10.4 million for the financial year that ended April 30 versus GBP13.1 million the year before. Pretax loss, however, narrows to GBP6.3 million from GBP18.3 million loss the year prior. This is due to non-repeat of GBP13.1 million of exceptional impairment losses on trade receivables and amounts recoverable on contracts. Separately, Kromek says it wins new contracts and orders across all segments for delivery this year.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
21 Mar 2024 13:10

Avacta reaches milestone in AVA6000 dose escalation

(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thursday.

Read more
21 Mar 2024 10:37

Avacta doses third patient in drug conjugate trial for tumour tissue

(Alliance News) - Avacta Group PLC on Thursday said it dosed the third patient in the first cohort of its phase 1a dose escalation study for its lead preCision drug AVA6000.

Read more
18 Mar 2024 14:31

IN BRIEF: Avacta shareholders give AGM go-ahead to issue new shares

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - At annual general meeting on Monday, shareholders approved the resolution to issue 23.9 million placing shares and 10.9 million Rex offer share, both at 50 pence each. This raises gross proceeds of around GBP11.9 million and GBP5.4 million respectively. Combined with proceeds from an earlier firm placing and direct subscription, the shares for which were admitted to trading on March 4, Avacta has raised total gross proceeds of GBP31.1 million.

Read more
5 Mar 2024 17:09

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
29 Feb 2024 12:18

Avacta increases placing size to GBP26 million thanks to strong demand

(Alliance News) - Avacta Group PLC on Thursday said it is increasing its placing to GBP25.7 million, "in light of the strong demand."

Read more
29 Feb 2024 10:27

AIM WINNERS & LOSERS: Beacon Energy and Avacta fall on fundraise

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
29 Feb 2024 08:27

Avacta tumbles after raising £25.7m in heavily discounted placing

(Sharecast News) - Healthcare therapeutics company Avacta tumbled on Thursday after a heavily discounted placing.

Read more
28 Feb 2024 20:31

TRADING UPDATES: Avacta plans fundraise to fund clinical development

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
19 Jan 2024 11:18

Avacta appoints new head of research and development

(Sharecast News) - Oncology drugs and diagnostics developer Avacta announced the appointment of Dr Christina Coughlin as its new head of research and development for the therapeutics division on Friday.

Read more
19 Jan 2024 09:11

IN BRIEF: Avacta says new head of R&D Coughlin brings "deep expertise"

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Appoints Christina Coughlin as head of research and development. Coughlin, who will take up the position on February 1, has served as a non-executive director of Avacta since March 2022 and was appointed consultant in interim in September 2023. She previously served as chief executive officer of Cytoimmune Therapeutics LLC, a clinical stage biotechnology company focused on novel cancer immunotherapy products. In the new role, Coughlin will oversee clinical and pre-clinical research and development activities for the company's therapeutics division, while retaining her position on as an executive director of Avacta. The company says that Coughlin has been "pivotal" in the development strategy for its AVA6000 tumour-targeted therapy.

Read more
19 Dec 2023 10:24

Avacta appoints new chief business officer

(Sharecast News) - Oncology drugs and diagnostics specialist Avacta Group announced the appointment of Dr Simon Bennett as the chief business officer of its therapeutics division on Tuesday.

Read more
19 Dec 2023 09:57

IN BRIEF: Avacta taps biopharma veteran as Therapeutics business chief

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Hires Simon Bennett as chief business officer of Therapeutics division. Says Bennett has over 26 years of commercial experience in the biopharma industry and has "worked with" various large and mid-sized companies like Bristol-Myers Squibb Co and Menarini Group.

Read more
13 Dec 2023 11:49

Avacta says study shows cancer treatment AVA6000 working as planned

(Alliance News) - Avacta Group PLC on Wednesday celebrated strong results from its latest cancer-targeting study, which showed the release of a chemotherapy to the tumour as intended.

Read more
13 Dec 2023 07:46

Avacta hails "encouraging" clinical data from cancer-targeting study

(Sharecast News) - Oncology drugs group Avacta has announced positive results from its lead pre|CISION programme, AVA6000, which it says has the potential to be "truly remarkable".

Read more
28 Sep 2023 11:08

IN BRIEF: Avacta loss widens on cost rise but clinical tests positive

Avacta Group PLC - Wetherby, England-based life sciences company that develops targeted oncology drugs and diagnostics - Pretax loss widens to GBP12.8 million in the six months that ended June 30 from GBP9.7 million a year before. Revenue doubles to GBP11.9 million from GBP5.5 million, but selling, general and administrative expenses near double as well, to GBP8.6 million from GBP4.7 million. Research costs are steady at GBP6.0 million. Has GBP26.0 million cash, up from GBP17.0 million a year before, though down from GBP41.8 million on December 31. Highlights success of AVA6000, a chemotherapy drug for cancer patients, in a Phase 1a clinical study. Avacta aims to complete a dose escalation safety study and provide results during the fourth quarter.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.